Boston Scientific (BSX) shares were in focus Wednesday after the medical device manufacturer reported third quarter results that were in line with analysts expectations. The company reported earnings of $0.27 a share, in line with expectations. Revenue of $2.11 billion, surpassed Wall Street's expectations of $2.07 billion
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.